

## Limited Submission Funding Opportunities – updated 12/31/21

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu)

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. Enhancing Systems of Care for Children with Medical Complexity (Demonstration Projects)

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334401>

**MGH LOI Deadline: 1/10/22**

NIH Application Deadline: 3/07/22

This notice announces the opportunity to apply for funding under the Enhancing Systems of Care for Children with Medical Complexity program. The purpose of this program is to optimize the health, quality of life,1,2,3 and well-being4 of children with medical complexity (CMC) and their families. The program will accomplish this by funding up to five demonstration projects (HRSA-22-098) to implement and evaluate evidence-informed, patient/family-centered models of care delivery, and by funding a

## Limited Submission Funding Opportunities – *updated 12/31/21*

coordinating center (HRSA-22-088) to provide support to the demonstration projects in meeting their program objectives, developing and disseminating resources, and providing leadership in the field.

### 2. Enhancing Systems of Care for Children with Medical Complexity (Coordinating Center)

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=334401>

**MGH LOI Deadline: 1/10/22**

NIH Application Deadline: 3/07/22

This notice announces the opportunity to apply for funding under the Enhancing Systems of Care for Children with Medical Complexity program. The purpose of this program is to optimize the health, quality of life,<sup>1,2,3</sup> and well-being<sup>4</sup> of children with medical complexity (CMC) and their families. The program will accomplish this by funding up to five demonstration projects (HRSA-22-098) to implement and evaluate evidence-informed, patient/family-centered models of care delivery, and by funding a coordinating center (HRSA-22-088) to provide support to the demonstration projects in meeting their program objectives, developing and disseminating resources, and providing leadership in the field.

### 3. Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-079.html>

**MGH LOI Deadline: 3/14/22**

NIH LOI Deadline: 5/03/22

NIH Application Deadline: 6/03/22

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.